ALX Oncology (NASDAQ:ALXO) said stockholders approved all proposals presented at the company’s 2026 annual meeting, including the election of three Class III directors, an advisory vote on executive compensation and the ratification of KPMG LLP as its independent auditor.
The annual meeting was held virtually on June 10, 2026. Jason Lettmann, chief executive officer of ALX Oncology Holdings, chaired the meeting and welcomed stockholders. Lettmann said the company continues to use a virtual format to broaden participation, saying ALX believes in “engaging with our stockholders and maximizing their ability to meaningfully engage with us.”
Directors Elected Through 2029
Stockholders elected Daniel Curran, Rekha Hemrajani and Chris Takimoto as Class III directors to serve until the company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to earlier resignation or removal.
Each nominee was already serving on ALX Oncology’s board of directors, according to the meeting transcript. The board had recommended that stockholders vote in favor of all three nominees.
Executive Compensation Approved
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers as described in the proxy statement. The non-binding “say on pay” proposal covered compensation disclosures made under Item 402 of Regulation S-K, including compensation tables and related narrative discussion.
The board of directors had recommended a vote in favor of the advisory executive compensation proposal.
KPMG Ratified as Independent Auditor
Stockholders ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. The company said that if stockholders had not ratified the appointment, the board could have reconsidered the selection.
The voting results announced at the meeting were preliminary. The company said final results may vary after the final examination of proxies and ballots and will be included in the Inspector of Election’s report. ALX also said final voting results will be reported in filings with the Securities and Exchange Commission.
CEO Highlights Clinical Pipeline Progress
Following the formal portion of the meeting, the company said no stockholder questions had been submitted. Lettmann then provided brief remarks on ALX Oncology’s clinical development programs.
Lettmann said the company made “significant progress” over the past year, citing advances in its lead program, evorpacept, and its novel EGFR-targeted antibody-drug conjugate, ALX2004. He said evorpacept is being advanced through a focused clinical development plan based on clinical proof of concept established in combination with anticancer antibodies across multiple studies.
He also said ALX2004 has progressed in Phase 1 dose escalation. Lettmann said the company expects to share additional data on both programs, with multiple clinical data readouts anticipated over the next 12 to 18 months.
“It is clearly a very exciting time at ALX,” Lettmann said, thanking stockholders for their attendance and support.
About ALX Oncology (NASDAQ:ALXO)
ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.
The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.
